HOME OF DENTAL PRODUCTS REPORT • DENTAL LAB PRODUCTS • MODERN HYGIENIST
Products
Printer Friendly
Email Article

Novartis Rolls Out Educational Dinner Meeting Series for GP Dentists

Benefits of Bisphosphonate Therapy vs Frequency of Oral Complications: An Educational Program for Dental Professionals


East Hanover, NJ, September 25, 2008 — Novartis Pharmaceuticals Corporation today announced the launch of a complimentary dental industry-focused dinner meeting series entitled “Benefits of Bisphosphonate Therapy vs Frequency of Oral Complications: An Educational Program for Dental Professionals.”

The dinner meetings are designed as an adjunct to Novartis’ recently-launched web seminar series and are being offered for dentists who prefer live seminars and the opportunity to interact with the presenters as well as their peers.

A total of ten 2-hour dinner meetings (www.oralhealthdinnermeeting.com) are to be hosted between September and December, and will be presented by a rotating roster of clinicians who are leading experts on this compelling and highly relevant subject.  

“Benefits of Bisphosphonate Therapy vs Frequency of Oral Complications: An Educational Program for Dental Professionals” will cover the following topics that every general practice dentist needs to know:

• Overview of bisphosphonates and uses in treatment of osteoporosis and metastatic bone disease

• Osteonecrosis of the jaw (ONJ) background

• ONJ frequency in oncology and osteoporosis patients treated with bisphosphonates

• Review of ONJ studies and management

The convenient schedule for the 10 Novartis dinner meetings is as follows:

City 

Date 

Time 

New Jersey      

Tues -10/14

7:00 PM

Philadelphia

Thurs -10/16

7:00 PM

New York City

Tues -10/21

7:00 PM

Boston

Thurs -10/23

7:00 PM

Miami 

Tues -10/28 

7:00 PM

Chicago

Thurs -10/30

7:00 PM

Detroit

Weds -11/05

7:00 PM

Dallas

Thurs -11/06

7:00 PM 

Los Angeles

Weds - 11/12

7:30 PM 

San Francisco

Thurs -11/13

7:00 PM 

 

 

 

       

For more details and to register for any dinner meeting session of “Benefits of Bisphosphonate Therapy vs Frequency of Oral Complications: An Educational Program for Dental Professionals,” visit www.oralhealthdinnermeeting.com.


****

About Novartis

Novartis Pharmaceuticals Corporation researches, develops, manufactures, and markets leading innovative prescription drugs used to treat a number of diseases and conditions, including those in the cardiovascular, metabolic, cancer, organ transplantation, central nervous system, dermatological, GI, and respiratory areas. The company's mission is to improve people's lives by pioneering novel healthcare solutions.

Located in East Hanover, New Jersey, Novartis Pharmaceuticals Corporation is an affiliate of Novartis AG (NYSE: NVS), which provides healthcare solutions that address the evolving needs of patients and societies. Focused solely on growth areas in healthcare, Novartis offers a diversified portfolio to best meet these needs: innovative medicines, cost-saving generic pharmaceuticals, preventive vaccines and diagnostic tools, and consumer health products. Novartis is the only company with leading positions in these areas. In 2007, the Group's continuing operations (excluding divestments in 2007) achieved net sales of USD 38.1 billion and net income of USD 6.5 billion. Approximately USD 6.4 billion was invested in R&D activities throughout the Group. Headquartered in Basel, Switzerland, Novartis Group companies employ approximately 98,200 full-time associates and operate in over 140 countries around the world. For more information, please visit http://www.novartis.com.
1 of 1
BROWSE BY CATEGORY